Health Care & Life Sciences » Pharmaceuticals | Corcept Therapeutics Inc.

Corcept Therapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
46,011.00
31,383.00
6,408.00
8,140.00
129,122.00
75,410
Depreciation, Depletion & Amortization
74.00
141.00
155.00
87.00
106.00
236
Other Funds
9,637.00
8,908.00
8,883.00
9,008.00
14,124.00
22,026
Funds from Operations
36,300.00
22,334.00
2,630.00
17,235.00
66,649.00
111,739
Changes in Working Capital
758.00
5,042.00
500.00
1,156.00
5,714.00
3,926
Net Operating Cash Flow
37,058.00
27,376.00
3,130.00
18,391.00
60,935.00
115,665
Capital Expenditures
127.00
174.00
17.00
194.00
419.00
Purchase/Sale of Investments
-
-
-
-
73,037.00
Net Investing Cash Flow
127.00
174.00
17.00
194.00
73,456.00
Issuance/Reduction of Debt, Net
1,025.00
4,856.00
9,207.00
14,779.00
15,134.00
Net Financing Cash Flow
970.00
3,079.00
13,074.00
7,096.00
7,953.00
Net Change in Cash
38,155.00
30,629.00
16,187.00
11,101.00
20,474.00
Free Cash Flow
37,185.00
27,550.00
3,113.00
18,197.00
60,516.00
Deferred Taxes & Investment Tax Credit
-
-
-
-
76,703.00
14,067
Change in Capital Stock
55.00
1,777.00
22,281.00
7,683.00
7,181.00

About Corcept Therapeutics

View Profile
Address
149 Commonwealth Drive
Menlo Park California 94025
United States
Employees -
Website http://www.corcept.com
Updated 07/08/2019
Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.